Pharmaceutical Corruption News Articles

Excerpts of key news articles on

Below are key excerpts of revealing news articles on pharmaceutical industry corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

For further exploration, delve into our comprehensive Health and Food Corruption Information Center.

Note: Explore our full index to revealing excerpts of key major media news articles on dozens of engaging topics. And read excerpts from 20 of the most revealing news articles ever published.

Thinking about going through your medicine cabinet and throwing out all your expired prescriptions? That might not be necessary, according to a UCSF-led study. Researchers analyzed eight prescription drugs with 15 active ingredients that expired between 28 and 40 years ago and found that most remained just as potent as they were on the day they were made. In 12 of the 14 drug compounds, or 86 percent of the time, the amount of active ingredient present in the drugs was at least 90 percent of the amount indicated on the label. That's well within the "reasonable variation" allowed by the U.S. Food and Drug Administration of 90 percent to 110 percent. Only two compounds - aspirin and the stimulant amphetamine - fell below the 90 percent threshold. Another medication, the painkiller phenacetin, fell below the threshold in one sample but was found in levels greater than 90 percent in another. The study was published online last week in the Archives of Internal Medicine.

Note: A drug listed expired as 40 years ago is still just as potent as the day it was made. Could short expiration dates be an example of drug companies finding a way to make more money through unnecessary disposal of older medications?

I remember the moment my son's teacher told us, "Just a little medication could really turn things around for Will." We stared at her as if she were speaking Greek. "Are you talking about Ritalin?" my husband asked. Will was in third grade, and his school wanted him to settle down in order to focus on math worksheets and geography lessons and social studies. The children were expected to line up quietly and "transition" between classes without goofing around. Will did not bounce off walls. He wasn't particularly antsy. He didn't exhibit any behaviors I'd associated with attention deficit or hyperactivity. He was an 8-year-old boy with normal 8-year-old boy energy - at least that's what I'd deduced from scrutinizing his friends. "He doesn't have attention deficit," I said. "We're not going to medicate him." Once you start looking for a problem, someone's going to find one, and attention deficit has become the go-to diagnosis, increasing by an average of 5.5 percent a year between 2003 and 2007, according to the Centers for Disease Control and Prevention. As of 2010, according to the National Health Interview Survey, 8.4 percent, or 5.2 million children, between the ages of 3 and 17 had been given diagnoses of attention deficit hyperactivity disorder. There's no clinical test for it: doctors make diagnoses based on subjective impressions from a series of interviews and questionnaires. I understand why the statistics are so high. In many cases, I discovered, diagnoses hinge on the teachers' [information].

Note: For deeply revealing reports from reliable major media sources on corruption in the medical-pharmaceutical complex, click here.

Why is a me-too drug for which there are much cheaper alternatives the second-best selling medicine in the United States? Today, IMS Health released its annual look at the sales of prescription drugs in America. It is the first year in which all of the top ten medicines in America are generics. This year, cancer drugs passed antipsychotic medicines as the top revenue generators. The biggest surprise ... is in the second-place spot: Nexium, ... from AstraZeneca, which generated $6.3 billion in sales. Abilify, from Otsuka and Bristol-Myers Squibb, passed Seroquel from Astra as the top-selling antipsychotic drug for disease like schizophrenia, bipolar disorder, and depression. Crestor, AstraZeneca’s cholesterol drug, has delivered a pretty stunning 5-year sales increase of 190%, apparently grabbing patients for whom Lipitor, from Pfizer, is not powerful enough. Sales do not equal popularity. Only three of these drugs (Lipitor, Plavix, and Singulair) rank among the top 25 most popular medicines. Price is often as big a component in making money as volume.

Propelled by an increase in prescription narcotic overdoses, drug deaths now outnumber traffic fatalities in the United States, a Times analysis of government data has found. Drugs exceeded motor vehicle accidents as a cause of death in 2009, killing at least 37,485 people nationwide, according to preliminary data from the U.S. Centers for Disease Control and Prevention. While most major causes of preventable death are declining, drugs are an exception. The death toll has doubled in the last decade, now claiming a life every 14 minutes. By contrast, traffic accidents have been dropping for decades because of huge investments in auto safety. This is the first time that drugs have accounted for more fatalities than traffic accidents since the government started tracking drug-induced deaths in 1979. Fueling the surge in deaths are prescription pain and anxiety drugs that are potent, highly addictive and especially dangerous when combined with one another or with other drugs or alcohol. Among the most commonly abused are OxyContin, Vicodin, Xanax and Soma. One relative newcomer to the scene is Fentanyl, a painkiller that comes in the form of patches and lollipops and is 100 times more powerful than morphine. Such drugs now cause more deaths than heroin and cocaine combined. Overdose victims range in age and circumstance from teenagers who pop pills to get a heroin-like high to middle-aged working men and women who take medications prescribed for strained backs and bum knees and become addicted. The seeds of the problem were planted more than a decade ago by well-meaning efforts by doctors to mitigate suffering, as well as aggressive sales campaigns by pharmaceutical manufacturers.

Note: For more on pharmaceutical industry corruption, see the deeply revealing reports from reliable major media sources available here.

One of the most financially successful cancer drugs in the world appears to cause more fatal side effects than previously realized, a new study says. Avastin, a blockbuster drug with more than $5.5 billion in global sales, increases the rate of fatal side effects by almost 50% when added to traditional chemotherapy, compared with chemo alone. About 2.5% of cancer patients who combine Avastin and chemo die from their treatment — rather than their disease, according to an analysis of 10,217 patients in today's Journal of the American Medical Association. In comparison, 1.7% of cancer patients who received only conventional chemo died as a result of therapy. The most common causes of death were hemorrhages, the loss of infection-fighting white blood cells, and perforations in the stomach or intestines, says Shenhong Wu of Stony Brook University School of Medicine, co-author of the analysis of 10,217 patients.

Note: Sadly, most studies that reveal such results are suppressed by the pharmaceutical industry.

When people consider the connections between drugs and violence, what typically comes to mind are illegal drugs like crack cocaine. However, certain medications most notably, some antidepressants like Prozac have also been linked to increase risk for violent, even homicidal behavior. A new study from the Institute for Safe Medication Practices published in the journal PloS One and based on data from the FDA's Adverse Event Reporting System has identified 31 drugs that are disproportionately linked with reports of violent behavior towards others. Please note that this does not necessarily mean that these drugs cause violent behavior. Nonetheless, when one particular drug in a class of nonaddictive drugs used to treat the same problem stands out, that suggests caution: unless the drug is being used to treat radically different groups of people, that drug may actually be the problem. Here are the top ten offenders: * 10. Desvenlafaxine (Pristiq) * 9. Venlafaxine (Effexor) * 8. Fluvoxamine (Luvox) * 7. Triazolam (Halcion) * 6. Atomoxetine (Strattera) * 5. Mefoquine (Lariam) * 4. Amphetamines: (Various) * 3. Paroxetine (Paxil) * 2. Fluoxetine (Prozac) * 1. Varenicline (Chantix)

Note: As mentioned in this article, all of these drugs are 8 to 18 times time more likely to be linked to violent acts than other drugs. For excellent reports on health issues from reliable sources, click here.

The Postal Service is ready to deliver lifesaving drugs to about a quarter of the residents of Minneapolis-St. Paul, the only metropolitan area in the nation where letter carriers have been trained to dispense medication after a large-scale terrorist attack involving biological weapons. Efforts are underway in six cities to train workers to deliver the drugs needed to counter anthrax or other potentially deadly agents, the White House says. The White House won't name the six cities, and Department of Homeland Security spokeswoman Amy Kudwa says she can't talk about whether more cities are interested in the voluntary program. With a model in place, the White House says it is working to expand the voluntary program to cities across the country. Minneapolis postal worker Chris Wittenburg of the National Association of Letter Carriers says setting up the program is complicated. First, letter carriers have to volunteer, undergo medical tests to make sure they can take the antibiotics, be fitted for masks (no facial hair allowed) and be trained. Routes have to be combined, and systems set up to suspend regular mail delivery in an instant, call postal workers in and send them out carrying boxes of drugs and fliers telling people what to do. About 60% of the city's letter carriers volunteered for the program, which was given a trial run in May.

Note: For lots more on the bogus "war on terror" and the anthrax attacks which helped to launch it, click here. For a recent key story on the many unanswered questions about the attacks, click here.

Drug company GlaxoSmithKline has told Canadian doctors to stop using one lot of its H1N1 vaccine until an investigation into a higher-than-expected number of severe allergic reactions is completed. The U.S. vaccine will not be identical to Arepanrix, the GSK H1N1 vaccine used in Canada. Arepanrix contains an adjuvant, a substance designed to boost the immune response, but adjuvants have never been approved for use in U.S. flu vaccines. Almost all of the 172,000 doses in question, distributed the week of Nov. 2 to six Canadian provinces, already have been administered, said Geoffrey Matthews, a spokeswoman for the Public Health Agency of Canada, which, with GSK and Health Canada, is investigating cases of anaphylaxis. Symptoms of anaphylaxis include trouble breathing, chest tightness and swelling of the mouth and throat. Six cases have been reported, Matthews says. In the USA, the Vaccine Adverse Event Reporting System said that as of Nov. 13 it had received 116 reports of serious health events related to the vaccine, including eight deaths – similar to the number in previous years after a similar number of seasonal flu vaccine doses had been shipped.

Note: For lots more on the risks of swine flu vaccines, click here.

Pharmaceutical firms need incentives, including lucrative patents, to keep creating drugs and vaccines against emergent threats such as the H1N1 influenza pandemic, the World Health Organization's head said on Tuesday. "Progress in public health depends on innovation. Some of the greatest strides forward for health have followed the development and introduction of new medicines and vaccines," said WHO Director-General Margaret Chan said. Chan, who last month declared a full pandemic underway from the H1N1 virus, said that patents can help ensure that companies develop medicines to "stay ahead of the development of drug resistance" in diseases like malaria and tuberculosis. The discovery of isolated H1N1 infections that resist the anti-viral Tamiflu, made by Roche and Gilead, and the global scramble to secure flu vaccines have shown the importance of robust research and development, Chan said. "Innovation is needed to keep pace with the emergence of new diseases, including pandemic influenza caused by the new H1N1 virus," she told a meeting on intellectual property and health, a contentious issue that has divided rich and poor nations.

Note: How much more blatant can it get? The WHO is telling us to pump money into the corrupt pharmaceutical corporations, who make huge profits from fear mongering and health disasters. When profit drives the health industry, which do you think comes first, money or public health? For lots more revealing, reliable information on the fear-mongering around swine flu, click here and here.

Pediatrician Rupin Thakkar's first inkling that the pharmaceutical industry was peering over his shoulder ... came in a letter from a drug representative about the generic drops Thakkar prescribes to treat infectious pinkeye. In the letter, the salesperson wrote that Thakkar was causing his patients to miss more days of school than they would if he put them on Vigamox, a more expensive brand-name medicine made by Alcon Laboratories. "My initial thought was 'How does she know what I'm prescribing?' " Thakkar said. "It feels intrusive ... I just feel strongly that medical encounters need to be private." He is not alone. Many doctors object to drugmakers' common practice of contracting with data-mining companies to track exactly which medicines physicians prescribe and in what quantities -- information marketers and salespeople use to fine-tune their efforts. The concerns are not merely about privacy. Proponents say using such detailed data for drug marketing serves mainly to influence physicians to prescribe more expensive medicines, not necessarily to provide the best treatment. "We don't like the practice, and we want it to stop," said Jean Silver-Isenstadt, executive director of the National Physicians Alliance. (Thakkar is on the group's board of directors.) "We think it's a contaminant to the doctor-patient relationship, and it's driving up costs." The American Medical Association makes millions of dollars each year by helping data-mining companies link prescribing data to individual physicians. It does so by licensing access to the AMA Physician Masterfile, a database containing names, birth dates, educational background, specialties and addresses for more than 800,000 doctors.

Note: For more reliable, verifiable information about major corruption in the drug industry, click here.

During your next routine medical checkup you have at least a 43 percent chance of undergoing an unnecessary medical test, a new study shows. It's not like you're getting something for nothing. If you're not having symptoms, and your doctor has no reason to suspect you have a problem, U.S. guidelines advise against giving you a routine urinalysis, electrocardiogram, or X-ray. "This has more harm than benefit," says Dan Merenstein, M.D., director of research in family medicine at Georgetown University. "The problem is, there are so many false-positive results from these tests. They lead to other things, like biopsies." The tests are meant to help doctors explore specific symptoms that are troubling patients or raise suspicion of a problem. If you're a healthy person who's just getting a routine checkup, there's only a tiny chance the tests will find disease. But Merenstein points out there's a good chance the tests will get a slightly abnormal finding. That means further costly tests — maybe even a painful biopsy — to show that you were, indeed, perfectly healthy to begin with. Aside from the costs in time and the potential for unnecessary suffering, these procedures add up to big money. Merenstein's modest estimate of the cost of just these three simple tests is $47 million to $194 million a year. And that doesn't include the cost of follow-up tests.

Note: For key reports from reliable sources on important health issues, click here.

A 15-month inquiry by a top House Democrat has found that enforcement of the nation's food and drug laws declined sharply during the first five years of the Bush administration. For instance, the investigation found, the number of warning letters that the Food and Drug Administration issued to drug companies, medical device makers and others dropped 54 percent, to 535 in 2005 from 1,154 in 2000. The seizure of mislabeled, defective or dangerous products dipped 44 percent. The research found no evidence that such declines could be attributed to increased compliance with regulations. Investigators at the F.D.A. continued to uncover about the same number of problems at drug and device companies as before...but top officials of the agency increasingly overruled the investigators' enforcement recommendations. The investigation found that by almost every measure, enforcement actions had significantly declined from 2000 to 2005. Dr. Sidney M. Wolfe, director of the Health Research Group at the watchdog organization Public Citizen, noted that the agency now received about $380 million a year in fees from drug makers. "The public," Dr. Wolfe said, "is getting the kind of F.D.A. that the industry is paying for them to get."

Note: For lots more on collusion between government and the medical industry, see our Health Information Center at http://www.WantToKnow.info/healthinformation

Drug companies fund a growing number of the studies in leading psychiatric journals, and drugs fare much better in these company-funded studies than in trials done independently or by competitors, researchers reported Wednesday. About 57% of published studies were paid for by drug companies in 2002, compared with 25% in 1992, says psychiatrist Igor Galynker of Beth Israel Medical Center in New York City. His team looked at clinical research in four influential journals: American Journal of Psychiatry, Archives of General Psychiatry, Journal of Clinical Psychiatry and Journal of Clinical Psychopharmacology. In the report, released at the American Psychiatric Association meeting in Toronto, reviewers did not know who paid for the studies they evaluated, Galynker says. There were favorable outcomes for a medication in about: eight out of 10 studies paid for by the company that makes the drug; five out of 10 studies done with no industry support; three out of 10 studies done by competitors of the firm making the drug. As drug companies increasingly fund research that yields favorable outcomes for their drugs, there may be a built-in bias because journals are reluctant to publish studies with negative or inconclusive findings.

Note: To learn more about the astonishing profits and power of the major drug companies, read our concise summary of a major insider's research at http://www.WantToKnow.info/healthcoverup

Cancer is not one disease. It is many. Yet oncologists have long used the same blunt weapons to fight different types of cancer: cut the tumour out, zap it with radiation or blast it with chemotherapy that kills good cells as well as bad ones. New cancer drugs are changing this. Scientists are now attacking specific mutations that drive specific forms of cancer. A breakthrough came more than a decade ago when Genentech, a Californian biotech firm, launched a drug that attacks breast-cancer cells with too much of a certain protein, HER2. In 2001 Novartis, a Swiss drugmaker, won approval for Gleevec, which treats chronic myeloid leukaemia by attacking another abnormal protein. Other drugs take different tacks. Avastin, introduced in America in 2004 by Genentech, starves tumours by striking the blood vessels that feed them. These new drugs sell well. Last year Gleevec grossed $4.3 billion. Roche’s Herceptin (the HER2 drug) and Avastin did even better: $6 billion and $7.4 billion respectively. The snag, from society’s point of view, is that all these drugs are horribly expensive. Last year biotech drugs accounted for 70% of the increase in pharmaceutical costs in America, according to Medco, a drug-plan manager. Cancer plays a huge role in raising costs.

Note: To see what happens when inexpensive potential cures for cancer are discovered, click here. For key reports on health issues from reliable sources, click here.

For the second time in two months, The Journal of the American Medical Association says it was misled by researchers who failed to reveal financial ties to drug companies. The latest incident, disclosed in letters to the editor and a correction in Wednesday's journal, involves a study showing that pregnant women who stop taking antidepressants risk slipping back into depression. Most of the 13 authors have financial ties to drug companies including antidepressant makers, but only two of them revealed their ties when the study was published in February.

Note: To understand how the drug companies manipulate results and even exert tremendous influence over the U.S. Congress, see http://www.WantToKnow.info/healthcoverup

Some of Britain’s leading scientists have accused the BBC of “quackery” by misleading viewers in an attempt to exaggerate the power of alternative medicine. The criticisms centre on Alternative Medicine, a series broadcast on BBC2 in January. The key critics include two scientific advisers to the series: Edzard Ernst, professor of complementary medicine at Exeter University; and George Lewith, director of the centre for the study of complementary medicine at Southampton University. Lewith, an expert on the effects of acupuncture, said in an interview yesterday: “The experiment was not groundbreaking; its results were sensationalised.” A [BBC] spokesman said yesterday: “We take these allegations very seriously and we strongly refute them. We used two scientific consultants for the series, Professor Ernst and Jack Tinker, dean emeritus of the Royal Society of Medicine, both of whom signed off the programme scripts. It seems extremely unusual that Professor Ernst should make these comments so long after the series has aired.” The spokesman said Tinker had indicated he remained happy with the tone and content of the films, stating: “Fellow medics at the Royal Society, including one eminent professor, said it was the best medical series they had seen on television.”

When Anya Bailey developed an eating disorder after her 12th birthday, her mother took her to a psychiatrist at the University of Minnesota who prescribed a powerful antipsychotic drug called Risperdal. Created for schizophrenia, Risperdal is not approved to treat eating disorders, but increased appetite is a common side effect and doctors may prescribe drugs as they see fit. Anya gained weight but within two years developed a crippling knot in her back. She now receives regular injections of Botox to unclench her back muscles. She often awakens crying in pain. Isabella Bailey, Anya’s mother, said she had no idea that children might be especially susceptible to Risperdal’s side effects. Nor did she know that Risperdal and similar medicines were not approved at the time to treat children. Just as surprising, Ms. Bailey said, was learning that the university psychiatrist who supervised Anya’s care received more than $7,000 from 2003 to 2004 from Johnson & Johnson, Risperdal’s maker, in return for lectures about one of the company’s drugs. The intersection of money and medicine, and its effect on the well-being of patients, has become one of the most contentious issues in health care. Nowhere is that more true than in psychiatry, where increasing payments to doctors have coincided with the growing use in children of a relatively new class of drugs known as atypical antipsychotics. These best-selling drugs, including Risperdal, Seroquel, Zyprexa, Abilify and Geodon, are now being prescribed to more than half a million children in the United States to help parents deal with behavior problems despite profound risks and almost no approved uses for minors.

Note: For lots more reliable information on cover-ups affecting your health, click here. To read an inspiring story on the benefits of healthy school diet for students' health, behavior and studies, click here.

The Bush administration said on Sunday that it would strenuously oppose one of the Democrats’ top priorities for the new Congress: legislation authorizing the government to negotiate with drug companies to secure lower drug prices for Medicare beneficiaries. In an interview, Michael O. Leavitt, the secretary of health and human services, said he saw no prospect of compromise on the issue. Dozens of plans are available in every state. They charge different premiums and co-payments and cover different drugs. The 2003 Medicare law explicitly prohibits the federal government from negotiating drug prices or establishing a list of preferred drugs. Representative Nancy Pelosi, the California Democrat who is in line to become the House speaker, has said the House will take up legislation to repeal that ban in its first 100 hours under Democratic control. Senate Democrats have expressed a similar desire. The eight Democrats newly elected to the Senate all say Medicare should have the power to negotiate with drug makers.

Note: To understand how the drug companies have become the most powerful lobby in government and will compromise our health for their profits, read what a top MD has to say by clicking here.

Medicare's drug benefit has given a shot in the arm to pharmaceutical companies and insurers, whose revenue is climbing thanks to government subsidies for prescription medicine. What's happened so far: Drugmakers including GlaxoSmithKline and Pfizer reported higher-than-expected sales and profit in the second quarter, with some of the momentum coming from Medicare. Meanwhile, membership rolls of big insurers, including UnitedHealth Group and Humana, are mushrooming as Medicare beneficiaries sign up for drug plans. Drug companies -- which successfully thwarted price-control attempts -- are reaping the rewards of more seniors and disabled people getting access to their medications. British drugmaker GlaxoSmithKline's second-quarter net income grew 14 percent over the same quarter last year due in part to strong Medicare drug sales. Merck & Co., Schering Plough, Wyeth, Roche and Pfizer ... all exceeded analysts' expectations, reflecting sales boosts from the program. In the first three months of the benefit, brand-name drug prices rose 4 percent, according to a report from the AARP. WellPoint Inc., the nation's largest insurer, reported second-quarter profit gains of 34 percent. UnitedHealth ... posted quarterly profit gains of 26 percent. Humana reported earlier this week its second-quarter profit increased 9.9 percent and revenue jumped 52 percent over the same quarter last year, due in large part to a surge in Medicare membership. The insurer expects annual revenue to grow by 50 percent.

Note: This article fails to mention who pays for all these profits -- our tax dollars. To understand the degree of corruption in the pharmaceutical industry, read a two-page summary by one of the most respected MDs in the U.S. at http://www.WantToKnow.info/healthcoverup

For years, scientists have looked at the placebo effect as just a figment of overactive patient imaginations. Sure, dummy medications seemed to curb epileptic seizures, lower blood pressure, soothe migraines and smooth out jerky movements in Parkinson's -- but these people weren't really better. Now, using PET scanners and MRIs ... researchers have discovered that the placebo effect is not "all in patients' heads" but rather, in their brains. New research shows that belief in a dummy treatment leads to changes in brain chemistry. Says Dr. Michael Selzer, professor of neurology at the University of Pennsylvania School of Medicine, "After pooh-poohing this for years, here are studies that show that our thoughts may actually interact with the brain in a physical way." New insights into how placebos work may even help scientists figure out how to harness the effect and teach people to train their own brains to help with healing. Studies in depressed patients ... have found that almost as many are helped by placebo treatments as by actual medications. Researchers are just starting to appreciate the power that the mind can have over the body. Part of what goes into the brain's interpretation is expectation. By changing the expectancy and bumping up the placebo response we might be able to ultimately find a way to provide sustained therapy for chronic pain.

Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.